Cav 2.2 blocker 1 is primarily used in research and therapeutic applications targeting N-type calcium channels, which play a critical role in pain signaling and neurotransmitter release. It is studied for its potential in managing chronic pain conditions, particularly neuropathic pain, by inhibiting these channels and reducing the transmission of pain signals. Additionally, it is explored for its role in neurological disorders where abnormal calcium channel activity is implicated. The compound is also utilized in pharmacological studies to better understand the function and regulation of Cav 2.2 channels in various physiological and pathological processes.